Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy
Background: Brentuximab vedotin (BV) and polatuzumab vedotin (PV), CD30-specific and CD79b-specific monoclonal antibody conjugates, respectively, are used in the treatment of hematologic cancers. Both have been observed to cause gastrointestinal adverse events (GI AEs). Objectives: We aimed to asses...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
SAGE Publishing
2026-02-01
|
| Ráidu: | Therapeutic Advances in Medical Oncology |
| Liŋkkat: | https://doi.org/10.1177/17588359261417635 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|